
Autoimmune pancreatitis: What we know so far
Author(s) -
Masood Muaaz
Publication year - 2022
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12688
Subject(s) - autoimmune pancreatitis , medicine , rituximab , malignancy , pancreatitis , disease , pancreas , pancreatic duct , dermatology , intensive care medicine , gastroenterology , immunology , lymphoma
Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can make the diagnosis challenging. Most patients have an excellent response to corticosteroid therapy. Immunomodulators may be used in some cases. Rituximab is an effective, emerging treatment in steroid‐refractory cases. This study aims to review the two distinct types of AIP and provide a detailed analysis of the diagnostic approach and treatment modalities.